2-[1-cyclobutanecarbonyl-6,8-bis(trifluoromethyl)-1H-pyrrolo[3,2-h]quinolin-2-yl]-1,3,4-oxadiazole,
1-[2-(1,3,4-oxadiazol-2-yl)-6,8-bis(trifluoromethyl)-1H-pyrrolo[3,2-h]quinolin-1-yl]ethan-1-one,
2-[4-chloro-2-(propan-2-yl)imidazo[1,2-a]1,8-naphthyridin-8-yl]-1,3,4-oxadiazole,
2-[6,8-bis(trifluoromethyl)imidazo[1,2-a]quinolin-2-yl]-1,3,4-oxadiazole,
8-(furan-2-yl)-2,4-bis(trifluoromethyl)imidazo[1,2-a]1,8-naphthyridine,
2-{2,4-dimethylimidazo[1,2-a]1,8-naphthyridin-8-yl}-1,3,4-oxadiazole,
2-[2,4-bis(trifluoromethyl)imidazo[1,2-a]1,8-naphthyridin-8-yl]-1,3-oxazole,
5-[6,8-bis(trifluoromethyl)-3H-imidazo[4,5-h]quinolin-2-yl]-1,3-oxazole,
2-[2-chloro-4-(trifluoromethyl)imidazo[1,2-a]1,8-naphthyridin-8-yl]-1,3,4-oxadiazole,
2-[2,4-bis(propan-2-yl)imidazo[1,2-a]1,8-naphthyridin-8-yl]-1,3,4-oxadiazole,
2-[4-phenyl-2-(propan-2-yl)imidazo[1,2-a]1,8-naphthyridin-8-yl]-1,3,4-oxadiazole,
and pharmaceutically acceptable salts thereof.

39. A pharmaceutical composition comprising a pharmaceutically acceptable diluent and a therapeutically effective amount of a compound as defined in any of the preceding claims.

40. The use of a compound or salt as defined in any of the preceding claims in the manufacture of a medicament for use in the treatment of a viral infection in a human.

41. The use of a compound as defined in any of claims 1 to 39 in the manufacture of a medicament ~~A method~~ for treating a common wart on a subject ~~comprising administering to the subject a compound of any one of claims 1 to 39~~.

~~42. A method for treating a common wart on a subject comprising contacting a compound of any one of claims 1 to 39 to the common wart on the subject.~~


~~43.~~42. The ~~method~~ use according to claim~~s~~ 41-~~42~~, wherein the compound is to be administered in a topical formulation.

~~44.~~43. The ~~method~~ use according to claim 41-~~42~~, wherein the common wart is caused by a human papillomavirus.

~~45.~~44. The ~~method~~ use according to claim~~s~~ 41-~~42~~, wherein the compound is formulated into a topical formulation for treating and/or preventing a dermatological condition resulting from a viral infection.


~~46.~~45. The ~~method~~ use according to claim ~~45~~44, wherein the compound is formulated into a topical formulation for preventing and/or treating a dermatological condition comprising warts.

~~47.~~46. ~~A method for treating a wart on the skin or mucous membrane of a subject comprising contacting~~ Use of a compound having the structure:



or a pharmaceutically acceptable salt thereof,
in the manufacture of a medicament for treating a wart on the skin or mucous membrane of a subject ~~to the wart on the skin or mucous membrane of the subject~~.

~~48.~~47. ~~A method for treating a wart on the skin or mucous membrane of a subject comprising contacting~~ Use of a compound having the structure:



or a pharmaceutically acceptable salt thereof,
in the manufacture of a medicament for treating a wart on the skin or mucous membrane of a subject comprising contacting~~to the wart on the skin or mucous membrane of the subject~~.

~~49.~~48. The use of a compound as defined in any of claims 1 to 39 in the manufacture of a medicament ~~A method~~ for treating a viral infection in a subject that has been diagnosed with said viral infection or is at risk of developing said viral infection ~~comprising administering to said subject, a compound of any one of claims 1 to 39~~.

~~50.~~49. The ~~method~~ use of claim ~~49~~48, wherein said viral infection comprises one or more viruses

from the Papillomavirus family.

~~51.~~50. The ~~method~~ use of claim ~~50~~49, wherein said viral infection comprises the human papillomavirus virus.

~~52.~~51. The use of a compound as defined in any of claims 1 to 39 in the manufacture of a medicament ~~A method~~ for enhancing the immune response in a subject that has been diagnosed with a viral infection or is at risk of developing said viral infection ~~comprising administering to said subject, a compound of any one of claims 1 to 39~~.

~~53.~~52. The use of a compound as defined in any of claims 1 to 39 in the manufacture of a medicament ~~A method~~ for enhancing the immune response to a viral infection in a subject that is immunocompromised or is at risk of developing an immunocomprised immune system ~~comprising administering to said subject, a compound of any one of claims 1 to 39~~.

~~54.~~53. The use of a compound as defined in any of claims 1 to 39 in the manufacture of a medicament ~~A method~~ for upregulating the JAK/STAT immune pathway in a subject that has been diagnosed with a viral infection or is at risk of developing said viral infection ~~comprising administering to said subject, a compound of any one of claims 1 to 39~~.

~~55.~~54. The use of a compound as defined in any of claims 1 to 39 in the manufacture of a medicament for ~~A method of~~ treating human papilloma virus associated skin diseases in a subject ~~comprising administering to the subject a compound of any one of claims 1 to 39~~.

~~56.~~55. The ~~method~~ use according to claim ~~55~~54, wherein the human papilloma virus associated skin disease comprises a disease that is selected from the group consisting of common warts, plantar warts, inguinal warts, venereal warts, and pre-cancerous lesions.

~~57.~~56. The use of a compound as defined in any of claims 1 to 39 in the manufacture of a medicament for ~~A method of~~ treating high risk human papilloma virus infections in a subject ~~comprising administering to the subject a compound of any one of claims 1 to 39~~.

~~58.~~57. The ~~method~~ use according to claim ~~57~~56, wherein the high risk human papilloma virus infection in the subject comprises a site selected from the group consisting of the cervix, vulva, vagina, penis, oropharynx, and anus.

~~59.~~58. The use of a compound as defined in any of claims 1 to 39 in the manufacture of a medicament for ~~A method of~~ topically treating human papilloma virus warts (verrucae) of the skin or mucous membranes of a subject ~~comprising administering to the subject a compound of any one of claims 1 to 39~~.

~~60.~~59. The use of a compound as defined in any of claims 1 to 39 in the manufacture of a medicament for ~~A method of~~ treating precancerous and cancerous skin lesions in a subject ~~comprising administering to the subject a compound of any one of claims 1 to 39~~.

~~61.~~60. The ~~method~~ use according to claim ~~60~~59, wherein the skin lesion comprises actinic keratoses.

~~62.~~61. The use of a compound as defined in any of claims 1 to 39 in the manufacture of a medicament for~~A method of~~ treating a viral skin infection comprising *molloscum contagiosum* in a subject ~~comprising administering to the subject a compound of any one of claims 1 to 39~~.

~~63.~~62. The use of an activator of a subject's JAK/STAT pathway in the manufacture of a medicament~~A method~~ for treating and/or preventing a viral infection in ~~a~~ the subject ~~comprising administering to the subject an activator of the subject's JAK/STAT pathway~~.

~~64.~~63. The ~~method~~ use according to claim ~~63~~62, wherein the activator is a chemical activator.

~~65.~~64. The ~~method~~ use according to claim ~~63~~62, wherein the activator is administered to the subject topically.

~~66.~~65. The ~~method~~ use according to claim ~~64~~63, wherein the chemical activator is a compound according to claim 1.

~~67.~~66. The ~~method~~ use according to claim ~~63~~65, wherein the viral infection is a viral infection of the subject's skin or mucous membranes.